aTyr Pharma, Inc. Common Stock
ATYRStock
$0.52−90.51%52W
Market Cap$51.08M
P/E—
Div yield—
Beta0.51
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-37.93%
Price vs S&P 500 (4W)18.72%
VGM Score12.10
Market Capitalization$51.08M
Earnings Surprise History
Q1 26-0.11est. -0.14
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.69
3.69
3.80
3.80
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ATYRaTyr Pharma, Inc. Common Stock | — | F | F | $0.52 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
aTyr Pharma develops biotherapeutics using a proprietary tRNA synthetase platform. Its lead candidate, efzofitimod, is a clinical-stage treatment that targets NRP2 to address chronic inflammation and fibrosis, particularly in lung disease. The approach exploits a novel mechanism based on the extracellular signaling pathways of tRNA synthetases.